FDA Accepts Eisai''s SNDA Application For ARICEPT® In The Treatment Of Severe Alzheimer''s Disease

... Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO Haruo Naito) and Eisai Inc. (Headquarters: Teaneck, NJ, Chairman and CEO Hajime Shimizu) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ARICEPT® (donepezil HCl tablets) for treatment of severe Alzheimer''s Disease... click link for more info. ...